Skip to main content
. Author manuscript; available in PMC: 2010 Jul 1.
Published in final edited form as: Anesthesiology. 2009 Jul;111(1):15–24. doi: 10.1097/ALN.0b013e3181a3276c

Table 1.

Summary information on deletions with unequivocal effects on halothane sensitivity

Strain Designation Location of deletion (Chromosome arm:genomic coordinate) Deletion size (bp) Δ potency (95% CL)
+/ED4065 2R:20290189 540173 −19.7% (−13.0 to −26.9)
+/ED5495 3R:5996223 716259 −25.0% (−15.6 to −35.9)
+/ED2247 2R:7487611 388614 −16.7% (−10.2 to −23.6)
+/ED2308 2R:8667875 216614 −16.6% (−10.1 to −23.5)
+/ED1725 2R:3501429 542121 +9.9% (+4.9 to +15.4)
+/ED1715 2R:3214456 589972 +9.2% (+4.2 to +14.5)
+/ED1 2R:12914232 70595 +16.1% (+10.6 to +22.5)
+/ED2751 2R:12744676 240132 +15.6% (+10.1 to +21.8)

The designated name indicates that the tested strains are heterozygotes between a strain without a deletion (+) and a strain (ED#) from the DrosDel collection carrying a deletion with the indicated number. The start point of each deletion is given with reference to the coordinate system of Drosophila Genome Release 5.1 (GenBank Accession AE013599.4 and AE014297.2). The change in potency of the deletion heterozygotes relative to the control heterozygote (+/parental ED line with no deletion) is deduced from eight-point concentration-response curves. These values, together with their 95% confidence limits, are calculated as described in Materials and Methods from the potency ratios derived from a logit analysis of the data.